A Phase 2 interventional study of Intensive Behavioral Program and Semaglutide and Behavioral Program in Obesity, Childhood, sponsored by University of Minnesota. Completed at 1 site in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by University of Minnesota · Phase 2, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Pediatric Obesity by University of Minnesota — 1 open to participants now, 1 under way, none of them phase 3. Pediatric Obesity · University of Minnesota.
Among the 20 studies in Pediatric Obesity by University of Minnesota, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2022, is one of 3 in phase 2, and was the 14th registered.
1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.
Browse Pediatric Obesity studies →1 of the 20 studies in Pediatric Obesity by University of Minnesota is open now, in 1 country. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 12–18
By country, each count listing its studies:
Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 100 across 872 interventional studies indexed under Pediatric Obesity.
Median enrollment 80 across the 19 interventional studies, 390 across the 1 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Minnesota is the lead sponsor of 1,219 studies on the registry; 199 are open to participants now.
Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Pediatric Obesity by University of Minnesota, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The prevalence of adolescent severe obesity is at an all-time high in the United States and the refractory nature of this disease has led to a serious and challenging conundrum in terms of how to provide effective, safe, scalable, and durable treatments without placing undue strain on the healthcare system. Clinical practice guidelines recommend behavioral interventions as the primary strategy for all ages and classes of obesity - moderate to severe. In 2017, the U.S. Preventive Services Task Force (USPSTF) released updated screening recommendations concluding that comprehensive, intensive behavioral interventions with a total of ≥26 contact hours over a period of 2-12 months resulted in weight loss in youth with obesity, with ≥52 contact hours leading to even greater weight loss and improvements in some cardiometabolic risk factors.
However, the practicality of delivering these types of intensive behavioral services to the millions of youth with severe obesity in the U.S. is debatable not only because of the treatment-resistant nature of severe obesity, but also due to the time-commitment, acceptability, and sustainability of this approach for adolescent patients and their families along with the extensive resources required to provide these interventions. Indeed, fewer than 50% of pediatric patients referred for weight management services enroll in treatment, and high attrition rates of up to 50% have been reported in behavioral-based clinical trials and in the clinical setting. Moreover, adherence to behavioral counseling significantly diminishes over time, which too often erodes early weight loss success and ultimately derails durability. The reality of what most patients/families are able to do and the unique physiological and psychosocial features of severe obesity in adolescence do not seem to align well with the degree of intensity of behavioral interventions shown to be effective by the USPSTF. Therefore, a critical appraisal of the feasibility, effectiveness, and sustainability of the USPSTF recommendations among adolescents with severe obesity is warranted.
While behavior change is an indispensable component of any effective weight loss approach, adjunctive strategies such as pharmacotherapy may enhance outcomes in adolescents with severe obesity. Many maladaptive behaviors attributed to obesity are driven by underlying biological forces, such as increased appetite and food palatability, that are largely beyond the control of the individual. Pharmacotherapy can help facilitate behavior change by disrupting core pathophysiological processes and restoring homeostasis to the energy regulatory system, therein enabling individuals to sustain healthy behavior change. Though under-explored as a treatment for adolescent obesity, pharmacotherapy along with relatively low-intensity behavioral counseling (\<26 contact hours) represents a potentially effective, durable, and safe treatment strategy. This approach may be more practical and feasible to implement on a broad scale, be preferred by patients/families, utilize fewer healthcare resources, and cost less to deliver compared to comprehensive, intensive behavioral interventions.
This is a two-arm, randomized clinical trial in adolescents with severe obesity evaluating 52 weeks of intensive behavioral counseling, aligned with USPSTF recommendations (52 contact hours), vs. 52 weeks of medical management with semaglutide (glucagon-like peptide-1 receptor agonist) plus relatively low-intensity behavioral counseling (12 contact hours).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm of the study will receive intensive behavioral therapy. Participants will receive 52 weekly sessions (50% in person and 50% virtual).
Behavioral: Intensive Behavioral Program
Participants randomized to this arm of the study will receive semaglutide and will receive behavioral therapy. Behavioral therapy will consist of 12 monthly sessions (50% in person and 50% virtual).
Drug: Semaglutide and Behavioral Program
Participants randomized to this group will receive intensive behavioral therapy.
Participants randomized to this group will receive semaglutide and behavioral therapy.
This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Percent Change in Body Mass Index
The percent change in body mass index (BMI) from Baseline to Week 56 will be calculated. BMI is defined as a person's weight in kilograms divided by the square of height in meters.
Time frame: Randomization to Week 56
Recruitment letters and flyers were utilized for this project.
| Milestone | Intensive Behavioral Program Arm | Medication Arm |
|---|---|---|
| Started | 61 | 60 |
| Completed | 50 | 58 |
| Not completed | 11 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 7 | 1 |
The percent change in body mass index (BMI) from Baseline to Week 56 will be calculated. BMI is defined as a person's weight in kilograms divided by the square of height in meters.
| % change in body mass index (BMI) | Intensive Behavioral Program Arm | Medication Arm |
|---|---|---|
| Percent Change in Body Mass Index | -1.8 ± 34 | -22.3 ± 34 |
Collected over All cause mortality, serious adverse event and adverse event information was collected from the time of consent until Week 56.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intensive Behavioral Program Arm | 0/61 (0%) | 2/61 (3.3%) | 34/61 (55.7%) |
| Medication Arm | 0/60 (0%) | 1/60 (1.7%) | 59/60 (98.3%) |
| Event | Intensive Behavioral Program Arm | Medication Arm |
|---|---|---|
| AppendicitisGastrointestinal disorders | 0/61 | 1/60 |
| Chemical Dependency TreatmentPsychiatric disorders | 1/61 | 0/60 |
| Suicidal Ideation hospitalizationPsychiatric disorders | 1/61 | 0/60 |
| Event | Intensive Behavioral Program Arm | Medication Arm |
|---|---|---|
| NauseaGastrointestinal disorders | 15/61 | 40/60 |
| Abdominal painGastrointestinal disorders | 16/61 | 33/60 |
| VomitingGastrointestinal disorders | 11/61 | 32/60 |
| DiarrheaGastrointestinal disorders | 10/61 | 30/60 |
| Abdominal DistensionGastrointestinal disorders | 4/61 | 18/60 |
| ConstipationGastrointestinal disorders | 6/61 | 15/60 |
| COVID InfectionInfections and infestations | 3/61 | 8/60 |
| DizzinessNervous system disorders | 0/61 | 8/60 |
| HeartburnGastrointestinal disorders | 6/61 | 7/60 |
| NasopharyngitisInfections and infestations | 5/61 | 6/60 |
| Age, Categorical(Participants) | Intensive Behavioral Program Arm | Medication Arm | Total |
|---|---|---|---|
| <=18 years | 61 | 60 | 121 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Intensive Behavioral Program Arm | Medication Arm | Total |
|---|---|---|---|
| Female | 37 | 38 | 75 |
| Male | 24 | 22 | 46 |
| Ethnicity (NIH/OMB)(Participants) | Intensive Behavioral Program Arm | Medication Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 3 | 11 |
| Not Hispanic or Latino | 53 | 57 | 110 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Intensive Behavioral Program Arm | Medication Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 4 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 11 | 9 | 20 |
| White | 40 | 43 | 83 |
| More than one race | 4 | 7 | 11 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | Intensive Behavioral Program Arm | Medication Arm | Total |
|---|---|---|---|
| United States | 61 | 60 | 121 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — To be determined
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Sharing will be available 10 years after the trial has been concluded.
Access criteria: Individuals should contact the study PI for information.
Ran from Mar 2022 to primary completion in Jun 2026, 51 months.
Results were first posted in Nov 2026, 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide